Proof of Concept Study of Vorinostat, A Histone Deacetylase Inhibitor, in Patients With Class 2 High Risk Uveal Melanoma
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Vorinostat (Primary)
- Indications Uveal melanoma
- Focus Pharmacodynamics; Pharmacogenomic; Proof of concept
- 04 Feb 2020 Planned End Date changed from 1 Jan 2027 to 29 Jan 2020.
- 04 Feb 2020 Planned primary completion date changed from 1 Jan 2022 to 29 Jan 2020.
- 04 Feb 2020 Status changed from suspended to withdrawn prior to enrolment.